AKBA

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease. Headquartered in Cambridge, Massachusetts, the company specializes in treatments addressing the consequences of chronic kidney disease (CKD), particularly anemia related to CKD and dialysis-dependent patients. Akebia's lead product, Auryxia (ferric citrate), is an FDA-approved oral medication indicated for the control of serum phosphorus in adult patients with dialysis-dependent CKD and for the treatment of iron deficiency anemia in adults with non-dialysis dependent CKD. The company's investigational drug vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), represents a novel approach to treating anemia in CKD patients and has undergone extensive Phase 3 clinical trials. Akebia collaborates with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of vadadustat in certain markets. The company operates with a commercial infrastructure targeting nephrologists and healthcare providers treating kidney disease patients across the United States. Akebia continues to advance its pipeline while building its commercial presence in the nephrology market, positioning itself as a dedicated player in addressing unmet needs within the kidney disease treatment landscape.